SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 6-K

                            Report of Foreign Issuer

    PURSUANT to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

                          For the Month of August, 2004
                         Commission File Number 0-30860

                                Axcan Pharma Inc.
                                -----------------
                           (Exact Name of Registrant)

         597, boul, Laurier, Mont-Saint-Hilaire (Quebec), Canada J3H 6C4
         ---------------------------------------------------------------
                    (Address of principal executive offices)

Indicate by check mark whether the registrant  files or will file annual reports
under cover Form 20-F or Form 40-F.


             Form 20-F       Form 40-F
                                 X
               ------          ------

Indicate by check mark whether the  registrant  by  furnishing  the  information
contained  in  this  Form is  also  hereby  furnishing  the  information  to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                 Yes            No
                                 X
               ------          ------


This Form 6-K consists of: A press release issued by Axcan Pharma Inc. on
August 5, 2004 entitled "Axcan Reports Third Quarter 2004 Results Revenue Up
32.3% To $62.0 Million."





                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                              AXCAN PHARMA INC.

Date: August 10, 2004         By:  /s/ Francois Painchaud
                                  -----------------------
                              Name:  Francois Painchaud
                              Title: Secretary and Director